SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

BMO Capital Maintains Outperform on bluebird bio, Raises Price Target to $112

BMO Capital maintains bluebird bio (NASDAQ:BLUE) with a Outperform and raises the price target from $107 to $112.

Benzinga · 05/12/2020 14:54

BMO Capital maintains bluebird bio (NASDAQ:BLUE) with a Outperform and raises the price target from $107 to $112.